Our mission is to improve the quality of life for BIPOC who are affected by IBD, Digestive Disorders and associated Chronic Illnesses; through Community, Research, Education, and Advocacy.

COGI’s Letter to CMS

COGI Calls on CMS to Protect Decisions Between Doctors and Patients by Covering Medications for Obesity and Ensuring Access to Prescribed Treatments

In response to a Centers for Medicare and Medicaid Services (CMS) proposed rule making, COGI expressed its support for CMS expanding coverage for anti-obesity medications when used to treat obesity in the Medicare Part D and Medicaid programs. Doing so will ensure all Americans living with obesity are able to access the care they need. In the letter, COGI’s founder Melodie Narain-Blackwell shared her own story of battling Inflammatory Bowel Disease and the positive impact of medication to manage her weight after giving birth to her daughter. By identifying obesity as a chronic disease and covering obesity medications, CMS will be raking a significant step toward curbing our nation’s chronic disease epidemic and promoting good health.

 

COGI is also supportive of CMS’s assertion that broad access to biosimilars is a necessary component of an appropriate utilization management program for Part D programs. Patients should have broad access to all the treatments that they and their doctors decide best to meet the patient’s needs, including biosimilar and generic drugs.

 

Click here to view COGI’s letter to CMS.

Join Our Community

Find us on the following platforms and join the conversation!

Subscribe to our newsletter!

Never miss an update. Receive periodic emails from us, and cancel at any time.

This field is for validation purposes and should be left unchanged.